{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T02:23:53Z","timestamp":1773887033412,"version":"3.50.1"},"reference-count":60,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medicina Cl\u00ednica"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.medcli.2021.02.010","type":"journal-article","created":{"date-parts":[[2021,4,5]],"date-time":"2021-04-05T19:43:35Z","timestamp":1617651815000},"page":"121-129","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Nefropat\u00eda membranosa primaria en la era de los autoanticuerpos y de las terapias biol\u00f3gicas"],"prefix":"10.1016","volume":"157","author":[{"given":"Jorge Enrique","family":"Rojas-Rivera","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Ortiz Ardu\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.medcli.2021.02.010_bib0305","doi-asserted-by":"crossref","first-page":"983","DOI":"10.2215\/CJN.11761116","article-title":"Primary membranous nephropathy","volume":"12","author":"Couser","year":"2017","journal-title":"Clin J Am Soc Nephrol."},{"key":"10.1016\/j.medcli.2021.02.010_bib0310","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa0810457","article-title":"M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy","volume":"361","author":"Beck","year":"2009","journal-title":"N Engl J Med."},{"key":"10.1016\/j.medcli.2021.02.010_bib0315","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1056\/NEJMoa1409354","article-title":"Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy","volume":"371","author":"Tomas","year":"2014","journal-title":"N Engl J Med."},{"key":"10.1016\/j.medcli.2021.02.010_bib0320","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1093\/ndt\/gfq665","article-title":"The incidence of primary glomerulonephritis worldwide: A systematic review of the literature","volume":"26","author":"McGrogan","year":"2011","journal-title":"Nephrol Dial Transplant."},{"key":"10.1016\/j.medcli.2021.02.010_bib0325","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1681\/ASN.2009080861","article-title":"Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy","volume":"21","author":"Polanco","year":"2010","journal-title":"J Am Soc Nephrol."},{"key":"10.1016\/j.medcli.2021.02.010_bib0330","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1111\/j.1600-6143.2008.02237.x","article-title":"Recurrent idiopathic membranous nephropathy after kidney transplantation: A surveillance biopsy study","volume":"8","author":"Dabade","year":"2008","journal-title":"Am J Transplant."},{"key":"10.1016\/j.medcli.2021.02.010_bib0335","first-page":"287","article-title":"Characterization of the antigen (gp600) of Heymann nephritis","volume":"50","author":"Makker","year":"1984","journal-title":"Lab Invest."},{"key":"10.1016\/j.medcli.2021.02.010_bib0340","first-page":"281","article-title":"Megalin\/lipoprotein receptor-related protein2 autoimmunity and kidney disease","volume":"13","author":"Perez-Gomez","year":"2020","journal-title":"Clin Kidney J."},{"key":"10.1016\/j.medcli.2021.02.010_bib0345","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1056\/NEJMoa012895","article-title":"Antenatal membranous glomerulonephritis due to anti-neutral endopeptidase antibodies","volume":"346","author":"Debiec","year":"2002","journal-title":"N Eng J Med."},{"key":"10.1016\/j.medcli.2021.02.010_bib0350","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1681\/ASN.2014050502","article-title":"Identification of a major epitope recognized by PLA2R autoantibodies in primary membranous nephropathy","volume":"26","author":"Fresquet","year":"2015","journal-title":"J Am Soc Nephrol."},{"key":"10.1016\/j.medcli.2021.02.010_bib0355","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1681\/ASN.2014111061","article-title":"Epitope spreading of autoantibody response to PLA2R associates with poor prognosis in membranous nephropathy","volume":"27","author":"Seitz-Polski","year":"2016","journal-title":"J Am Soc Nephrol."},{"key":"10.1016\/j.medcli.2021.02.010_bib0360","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.3390\/jcm9072178","article-title":"Tacrolimus prevents TWEAK-induced PLA2R expression in cultured human podocytes","volume":"9","author":"Cuarental","year":"2020","journal-title":"J Clin Med."},{"key":"10.1016\/j.medcli.2021.02.010_bib0365","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1172\/JCI85265","article-title":"Autoantibodies against thrombospondin type-1 domain-containing 7A induce membranous nephropathy","volume":"126","author":"Tomas","year":"2016","journal-title":"J Clin Invest."},{"key":"10.1016\/j.medcli.2021.02.010_bib0370","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1093\/ndt\/gfv228","article-title":"Spontaneous remission of proteinuria is a frequent event in phospholipase A2 receptor antibody-negative patients with membranous nephropathy","volume":"30","author":"Hoxha","year":"2015","journal-title":"Nephrol Dial Transplant."},{"key":"10.1016\/j.medcli.2021.02.010_bib0375","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.2215\/CJN.01460217","article-title":"Circulating antibodies against thrombospondin type-1 domain-containing A in Chinese patients with idiopathic membranous nephropathy","volume":"12","author":"Wang","year":"2017","journal-title":"Clin J Am Soc Nephrol."},{"key":"10.1016\/j.medcli.2021.02.010_bib0380","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMc1511702","article-title":"A mechanism for cancer-associated membranous nephropathy","volume":"374","author":"Hoxha","year":"2016","journal-title":"N Eng J Med."},{"key":"10.1016\/j.medcli.2021.02.010_bib0385","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1681\/ASN.2008121259","article-title":"Autoimmunity in membranous nephropathy targets aldose reductase and SOD2","volume":"3","author":"Prunotto","year":"2010","journal-title":"J Am Soc Nephrol."},{"key":"10.1016\/j.medcli.2021.02.010_bib0390","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1681\/ASN.2018080852","article-title":"Exostosin 1\/Exostosin2-associated membranous nephropathy","volume":"30","author":"Sethi","year":"2019","journal-title":"J Am Soc Nephrol."},{"key":"10.1016\/j.medcli.2021.02.010_bib0395","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.kint.2019.09.014","article-title":"Neural epidermal growth factor-like1 protein (NELL-1) associated membranous nephropathy","volume":"97","author":"Sethi","year":"2020","journal-title":"Kidney Int."},{"key":"10.1016\/j.medcli.2021.02.010_bib0400","article-title":"NELL1 is a target antigen in malignancy-associated membranous nephropathy","author":"Caza","year":"2020","journal-title":"Kidney Int."},{"key":"10.1016\/j.medcli.2021.02.010_bib0405","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/j.kint.2020.05.030","article-title":"Semaphorin 3B-associated membranous nephropathy is a distinct type of disease predominantly present in pediatric patients","volume":"98","author":"Sethi","year":"2020","journal-title":"Kidney Int."},{"key":"10.1016\/j.medcli.2021.02.010_bib0410","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/1423-0127-17-81","article-title":"Association of phospholipase A2 receptor1 polymorphins with idiopathic membranous nephropathy in Chinese patients in Taiwan","volume":"17","author":"Liu","year":"2010","journal-title":"J Biom Sci."},{"key":"10.1016\/j.medcli.2021.02.010_bib0415","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1056\/NEJMoa1009742","article-title":"Risk HLA-DQA1 and PLA(2)R1 alleles in idiopathic membranous nephropathy","volume":"364","author":"Stanescu","year":"2011","journal-title":"N Eng J Med."},{"key":"10.1016\/j.medcli.2021.02.010_bib0420","doi-asserted-by":"crossref","first-page":"335","DOI":"10.2215\/CJN.05310513","article-title":"HLA-DQA1 and PLA2R1 polymorphisms and risk of idiopathic membranous nephropathy","volume":"9","author":"Bullich","year":"2014","journal-title":"Clin J Am Soc Nephrol."},{"key":"10.1016\/j.medcli.2021.02.010_bib0425","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1681\/ASN.2016010093","article-title":"Long-term exposure to air pollution and increased risk of membranous nephropathy in China","volume":"27","author":"Xu","year":"2016","journal-title":"J Am Soc Nephrol."},{"key":"10.1016\/j.medcli.2021.02.010_bib0430","doi-asserted-by":"crossref","first-page":"3539","DOI":"10.1681\/ASN.2015101155","article-title":"Phospholipase A2 receptor-related membranous nephropathy and mannan-biding lectin deficiency","volume":"27","author":"Bally","year":"2016","journal-title":"J Am Soc Nephrol."},{"key":"10.1016\/j.medcli.2021.02.010_bib0435","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1056\/NEJMc1805857","article-title":"FactorH autoantibodies and membranous nephropathy","volume":"379","author":"Seikrit","year":"2018","journal-title":"N Eng J Med."},{"key":"10.1016\/j.medcli.2021.02.010_bib0440","doi-asserted-by":"crossref","first-page":"7638365","DOI":"10.1155\/2020\/7638365","article-title":"The potential role of regulatory Bcells in idiopathic membranous nephropathy","volume":"2020","author":"Dong","year":"2020","journal-title":"J Immunol Res."},{"key":"10.1016\/j.medcli.2021.02.010_bib0445","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.574997","article-title":"Th17-immune response in patients with membranous nephropathy is associated with thrombosis and relapses","author":"Cremoni","year":"2020","journal-title":"Frontiers Immunol."},{"key":"10.1016\/j.medcli.2021.02.010_bib0450","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.kint.2018.10.021","article-title":"Noninvasive diagnosis of primary membranous nephropathy using phospholipase A2 receptor antibodies","volume":"95","author":"Bobart","year":"2019","journal-title":"Kidney Int."},{"key":"10.1016\/j.medcli.2021.02.010_bib0455","doi-asserted-by":"crossref","first-page":"e104936","DOI":"10.1371\/journal.pone.0104936","article-title":"The diagnosis accuracy of PLA2R AB in the diagnosis of idiopathic membranous nephropathy: A meta-analysis","volume":"9","author":"Du","year":"2014","journal-title":"PLoS One."},{"key":"10.1016\/j.medcli.2021.02.010_bib0460","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1681\/ASN.2016070776","article-title":"A proposal for a serology-based approach to membranous nephropathy","volume":"28","author":"De Vriese","year":"2017","journal-title":"J Am Soc Nephrol."},{"key":"10.1016\/j.medcli.2021.02.010_bib0465","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.2215\/CJN.07210810","article-title":"Anti-phospholipase A2 receptor antibodies correlate with clinical status in idiopathic membranous nephropathy","volume":"6","author":"Hofstra","year":"2011","journal-title":"Clin J Am Soc Npehrol."},{"key":"10.1016\/j.medcli.2021.02.010_bib0470","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1038\/ki.2012.486","article-title":"Anti-PLA2R antibodies measured by ELISA predict long-term outcome in a prevalent population of patients with idiopathic membranous nephropathy","volume":"83","author":"Kanigicherla","year":"2013","journal-title":"Kidney Int."},{"key":"10.1016\/j.medcli.2021.02.010_bib0475","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.2215\/CJN.10471013","article-title":"Association of anti-PLA2R antibodies with outcomes after immunosuppressive therapy in idiopathic membranous nephropathy","volume":"9","author":"Bech","year":"2014","journal-title":"Clin J Am Soc Nephrol."},{"key":"10.1016\/j.medcli.2021.02.010_bib0480","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1093\/ndt\/gfu252","article-title":"Prediction of membranous nephropathy recurrence after transplantation by monitoring of anti-PLA2R1 (M-type phospholipase A2 receptor) autoantibodies: A case serie of 15 patients","volume":"29","author":"Seitz-Polski","year":"2014","journal-title":"Nephrol Dial Transplant."},{"key":"10.1016\/j.medcli.2021.02.010_bib0485","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1111\/j.1600-6143.2011.03643.x","article-title":"Autoantibodies specific for the phospholipase A2 receptor in recurrent and de novo membranous nephropathy","volume":"11","author":"Debiec","year":"2011","journal-title":"Am J Transplant."},{"key":"10.1016\/j.medcli.2021.02.010_bib0490","first-page":"186","article-title":"Kidney disease: Improving global outcomes (KDIGO) glomerulonephritis work group. KDIGO clinical practice guidelines for glomerulonephritis","volume":"2","year":"2012","journal-title":"Kidney Int Suppl."},{"key":"10.1016\/j.medcli.2021.02.010_bib0495","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"New Eng J Med."},{"key":"10.1016\/j.medcli.2021.02.010_bib0500","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1056\/NEJM198901053200102","article-title":"A randomized trial of methylprednisolone and chlorambucil in idiopathic membranous nephropathy","volume":"320","author":"Ponticelli","year":"1989","journal-title":"N Engl J Med."},{"key":"10.1016\/j.medcli.2021.02.010_bib0505","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1681\/ASN.V93444","article-title":"A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy","volume":"9","author":"Ponticelli","year":"1998","journal-title":"J Am Soc Nephrol."},{"key":"10.1016\/j.medcli.2021.02.010_bib0510","article-title":"The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy","author":"Fern\u00e1ndez-Ju\u00e1rez","year":"2020","journal-title":"Kidney Int."},{"key":"10.1016\/j.medcli.2021.02.010_bib0515","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1046\/j.1523-1755.2001.0590041484.x","article-title":"Cyclosporine in patients with steroid-resistant membranous nephropathy: A randomized trial","volume":"59","author":"Cattran","year":"2001","journal-title":"Kidney Int."},{"key":"10.1016\/j.medcli.2021.02.010_bib0520","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1038\/sj.ki.5002215","article-title":"Tacrolimus monotherapy in membranous nephropathy: A randomized controlled trial","volume":"71","author":"Praga","year":"2007","journal-title":"Kidney Int."},{"key":"10.1016\/j.medcli.2021.02.010_bib0525","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1053\/j.ajkd.2008.04.013","article-title":"Mycophenolate mofetil monotherapy in membranous nephropathy: A 1-year randomized controlled trial","volume":"52","author":"Dussol","year":"2008","journal-title":"Am J Kidney Dis."},{"key":"10.1016\/j.medcli.2021.02.010_bib0530","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1053\/j.ajkd.2005.10.016","article-title":"A randomized pilot trial comparing methylprednisolone plus a cytotoxic agent versus synthetic adrenocorticotropic hormone in idiopathic membranous nephropathy","volume":"47","author":"Ponticelli","year":"2006","journal-title":"Am J Kidney Dis."},{"key":"10.1016\/j.medcli.2021.02.010_bib0535","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1159\/000339287","article-title":"Treatment of resistant glomerular diseases with adrenocorticotropic hormone gel: a prospective trial","volume":"36","author":"Bomback","year":"2012","journal-title":"Am J Nephrol."},{"key":"10.1016\/j.medcli.2021.02.010_bib0540","doi-asserted-by":"crossref","first-page":"e0142033","DOI":"10.1371\/journal.pone.0142033","article-title":"Synthetic ACTH in high risk patients with idiopathic membranous nephropathy: A prospective, open label cohort study","volume":"10","author":"Van de Logt","year":"2015","journal-title":"PLoS One."},{"key":"10.1016\/j.medcli.2021.02.010_bib0545","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1681\/ASN.2012020181","article-title":"Rituximab in idiopathic membranous nephropathy","volume":"23","author":"Ruggenenti","year":"2012","journal-title":"J Am Soc Nephrol."},{"key":"10.1016\/j.medcli.2021.02.010_bib0550","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.2215\/CJN.06041108","article-title":"Successful treatment of membranous glomerulonephritis with rituximab in calcineurin inhibitor-dependent patients","volume":"4","author":"Segarra","year":"2009","journal-title":"Clin J Am Soc Nephrol."},{"key":"10.1016\/j.medcli.2021.02.010_bib0555","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1681\/ASN.2016040449","article-title":"Rituximab for severe membranous nephropathy: A 6-month trial with extended follow-up","volume":"28","author":"Dahan","year":"2017","journal-title":"J Am Soc Nephrol."},{"key":"10.1016\/j.medcli.2021.02.010_bib0560","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJMoa1814427","article-title":"Rituximab or cyclosporine in the treatment of membranous nephropathy","volume":"381","author":"Fervenza","year":"2019","journal-title":"N Engl J Med."},{"key":"10.1016\/j.medcli.2021.02.010_bib0605","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1681\/ASN.2020071091","article-title":"Rituximab or cyclophosphamide in the treatment of membranous nephropathy: the RI-CYCLO randomized trial","volume":"32","author":"Scolari","year":"2021","journal-title":"J Am Soc Nephrol."},{"key":"10.1016\/j.medcli.2021.02.010_bib0570","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.ekir.2019.12.006","article-title":"Rituximab in patients with phospholipase A2 receptor-associated membranous nephropathy and severe CKD","volume":"5","author":"Hanset","year":"2020","journal-title":"Kidney Int Rep."},{"key":"10.1016\/j.medcli.2021.02.010_bib0575","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/S0140-6736(12)61566-9","article-title":"Immunosuppression for progressive membranous nephropathy: A UK randomized controlled trial","volume":"381","author":"Howman","year":"2013","journal-title":"Lancet."},{"key":"10.1016\/j.medcli.2021.02.010_bib0580","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1053\/j.ajkd.2020.02.444","article-title":"Successful treatment of patient with refractory PLA2R-associated membranous nephropathy with obitunuzumab: A report of 3 cases","volume":"76","author":"Klomjit","year":"2020","journal-title":"Am J Kidney Dis."},{"key":"10.1016\/j.medcli.2021.02.010_bib0585","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/j.ekir.2020.06.030","article-title":"Obinutuzumab is effective for the treatment of refractory membranous nephropathy","volume":"5","author":"Sethi","year":"2020","journal-title":"Kidney Int Rep."},{"key":"10.1016\/j.medcli.2021.02.010_bib0590","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa2001180","article-title":"Two-year, randomized, controlled trial of belimumab in lupus nephritis","volume":"383","author":"Furie","year":"2020","journal-title":"N Eng J Med."},{"key":"10.1016\/j.medcli.2021.02.010_bib0595","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1093\/ndt\/gfz086","article-title":"Effect of belimumab on proteinuria and anti-phospholipase A2 receptor autoantibody in membranous nephropathy","volume":"35","author":"Barret","year":"2020","journal-title":"Nephrol Dial Transplant."},{"key":"10.1016\/j.medcli.2021.02.010_bib0600","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s40620-013-0028-x","article-title":"Bortezomib therapy for nephrotic syndrome due to idiopathic membranous nephropathy","volume":"27","author":"Hartono","year":"2014","journal-title":"J Nephrol."}],"container-title":["Medicina Cl\u00ednica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775321001299?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775321001299?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T01:52:31Z","timestamp":1758419551000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025775321001299"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":60,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["S0025775321001299"],"URL":"https:\/\/doi.org\/10.1016\/j.medcli.2021.02.010","relation":{},"ISSN":["0025-7753"],"issn-type":[{"value":"0025-7753","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nefropat\u00eda membranosa primaria en la era de los autoanticuerpos y de las terapias biol\u00f3gicas","name":"articletitle","label":"Article Title"},{"value":"Medicina Cl\u00ednica","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medcli.2021.02.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}